NDAORALTABLET
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
3/8 — Basic
WIDAPLIK (telmisartan, amlodipine and indapamide) by R-Pharm US is angiotensin 2 receptor antagonists [moa]. First approved in 2025.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WIDAPLIK is a fixed-dose combination tablet containing telmisartan (ARB), amlodipine (calcium channel blocker), and indapamide (thiazide diuretic) for oral administration. It targets hypertension through triple-mechanism action: blocking angiotensin II receptors, reducing vascular calcium influx, and increasing sodium/water excretion. The product represents a multi-modal approach to blood pressure control in patients requiring intensified antihypertensive therapy.
Growth11.7 years to LOE
Early-stage launch product with no established competitor pressure indicates opportunity for brand-building teams to capture market share in the combination antihypertensive segment.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
WIDAPLIK represents a launch-stage opportunity for professionals seeking to build a brand from market entry in the high-volume hypertension category. Career growth will depend on establishing market share in a competitive but undifferentiated space, with focus on provider education, payer relationships, and patient access programs.
Brand Manager
Worked on WIDAPLIK at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.